Article info
PDFLaw, ethics and medicine
Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
- Professor E Jackson, Law Department, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK; e.jackson{at}lse.ac.uk
Citation
Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
Publication history
- Received March 28, 2008
- Revised July 28, 2008
- Accepted August 14, 2008
- First published January 30, 2009.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group & Institute of Medical Ethics
Other content recommended for you
- UK government tightens rules on drug trial results
- What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
- Agency warns of withdrawal risks for patients taking SSRIs
- DTB Select: 5 | May 2015
- The licensing of medicines in the UK
- Is there a cure for corporate crime in the drug industry?
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review
- Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011)
- Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports
- Did regulators fail over selective serotonin reuptake inhibitors?